So far this year, Eli Lilly (NYSE: LLY) has been on an absolute tear and is swiftly becoming the world's most prolific ...

Viking's clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of ...

In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

Research results featured heavily in the news last week, first with Viking Therapeutics releasing promising early-stage data ...

When it comes to pre-revenue biotechs, it's often a struggle to build an investment thesis beyond "if the medicine works, the ...